Stephane Nave
Overview
Explore the profile of Stephane Nave including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
195
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Taher A, Viprakasit V, Cappellini M, Kraus D, Cech P, Volz D, et al.
Br J Haematol
. 2021 May;
194(2):474-477.
PMID: 33931857
No abstract available.
2.
Hipp J, Knoflach F, Comley R, Ballard T, Honer M, Trube G, et al.
Sci Rep
. 2021 Apr;
11(1):7700.
PMID: 33833333
GABA-α5 subunit-containing receptors have been shown to play a key modulatory role in cognition and represent a promising drug target for cognitive dysfunction, as well as other disorders. Here we...
3.
Sergott R, Amorelli G, Baranello G, Barreau E, Beres S, Kane S, et al.
Ann Clin Transl Neurol
. 2020 Nov;
8(1):54-65.
PMID: 33231373
Objective: Evaluation of ophthalmologic safety with focus on retinal safety in patients with spinal muscular atrophy (SMA) treated with risdiplam (EVRYSDI®), a survival of motor neuron 2 splicing modifier associated...
4.
Li Z, Mirams G, Yoshinaga T, Ridder B, Han X, Chen J, et al.
Clin Pharmacol Ther
. 2019 Nov;
107(1):102-111.
PMID: 31709525
This white paper presents principles for validating proarrhythmia risk prediction models for regulatory use as discussed at the In Silico Breakout Session of a Cardiac Safety Research Consortium/Health and Environmental...
5.
Borroni E, Bohrmann B, Grueninger F, Prinssen E, Nave S, Loetscher H, et al.
J Pharmacol Exp Ther
. 2017 Jun;
362(3):413-423.
PMID: 28642233
Monoamine oxidase B (MAO-B) has been implicated in the pathogenesis of Alzheimer's disease (AD) and other neurodegenerative disorders. Increased MAO-B expression in astroglia has been observed adjacent to amyloid plaques...
6.
Nave S, Doody R, Boada M, Grimmer T, Savola J, Delmar P, et al.
J Alzheimers Dis
. 2017 May;
58(4):1217-1228.
PMID: 28550255
Background: Sembragiline is a potent, selective, long-acting, and reversible MAO-B inhibitor developed as a potential treatment for Alzheimer's disease (AD). Objective: To evaluate the safety, tolerability, and efficacy of sembragiline...
7.
Sturm S, Forsberg A, Nave S, Stenkrona P, Seneca N, Varrone A, et al.
Eur J Nucl Med Mol Imaging
. 2016 Sep;
44(3):382-391.
PMID: 27633250
Purpose: In Alzheimer's disease (AD), increased metabolism of monoamines by monoamine oxidase type B (MAO-B) leads to the production of toxic reactive oxygen species (ROS), which are thought to contribute...
8.
Robert P, Konig A, Amieva H, Andrieu S, Bremond F, Bullock R, et al.
Front Aging Neurosci
. 2014 Apr;
6:54.
PMID: 24715864
Alzheimer's disease and other related disorders (ADRD) represent a major challenge for health care systems within the aging population. It is therefore important to develop better instruments to assess the...
9.
Linssen A, Vuurman E, Sambeth A, Nave S, Spooren W, Vargas G, et al.
Psychopharmacology (Berl)
. 2011 May;
218(3):533-42.
PMID: 21597989
Rationale: The basal ganglia play an important role in motor control, which is dependent on dopaminergic input. Preparation of a motor response has been associated with dopamine release in the...
10.
Bellibas S, Patel I, Chamorey E, Brivet B, Bush E, Kircher C, et al.
Clin Cancer Res
. 2004 Apr;
10(7):2327-35.
PMID: 15073108
Purpose: Ro 09-4889 was designed to enhance the anticancer efficacy of capecitabine (Xeloda) by generating a dihydropyrimidine dehydrogenase inhibitor (DPDi) 5-vinyluracil (5-VU) preferentially in tumor tissues. This study assessed the...